32 research outputs found
Pex5p, the peroxisomal cycling receptor, is a monomeric non-globular protein
In mammals, targeting of newly synthesized peroxisomal matrix proteins to the organelle requires Pex5p, the peroxisomal cycling receptor. Pex5p is a multidomain protein involved in a complex network of transient protein-protein interactions. Besides interacting directly with most peroxisomal proteins en route to the organelle, Pex5p has also binding domains for several components of the peroxisomal docking/translocation machinery. However, our knowledge of how binding of a cargo protein to Pex5p influences its properties is still rather limited. Here, we describe a protease assay particularly useful for identifying and characterizing protein-protein interactions involving human Pex5p. Binding of a PTS1-containing peptide/ protein to Pex5p as well as the interaction of this peroxin with the Src homology domain 3 of Pex13p could be easily demonstrated using this assay. To address the possible effects of these Pex5p-interacting peptides/proteins on the assumed quaternary structure of Pex5p, we have analyzed the hydrodynamic properties of human Pex5p using size exclusion chromatography, sucrose gradient centrifugation, and sedimentation equilibrium centrifugation. Our results show that Pex5p is a monomeric protein with an abnormal shape. The implications of these findings on current models of protein translocation across the peroxisomal membrane are discussed
The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model
Background: The farnesoid X receptor (FXR) influences hepatic metabolism, inflammation
and liver fibrosis as key components of non-alcoholic steatohepatitis (NASH). We studied the effects
of the non-steroidal FXR agonist cilofexor (formerly GS-9674) on portal pressure and fibrosis in
experimental NASH. Methods: NASH was induced in Wistar rats using a choline-deficient high-fat
diet plus intraperitoneal sodium nitrite injections. First, a dose-finding study was performed with
10 mg/kg and 30 mg/kg of cilofexor, focusing on histological readouts. Liver fibrosis was assessed
by Picro-Sirius-Red, desmin staining and hepatic hydroxyproline content. Gene expression was
determined by RT-PCR. In a subsequent hemodynamic study, rats received 30 mg/kg cilofexor with
or without propranolol (25 mg/kg). Portal pressure, systemic hemodynamics and splanchnic blood
flow were measured. Results: Cilofexor dose-dependently induced FXR target genes shp, cyp7a1
and fgf15 in hepatic and ileal tissues, paralleled by a dose-dependent reduction in liver fibrosis
area (Picro-Sirius-Red) of −41% (10 mg/kg) and −69% (30 mg/kg), respectively. The 30 mg/kg
cilofexor dose significantly reduced hepatic hydroxyproline content (−41%), expression of col1a1
(−37%) and pdgfr-β (−36%), as well as desmin area (−42%) in NASH rats. Importantly, cilofexor
decreased portal pressure (11.9 ± 2.1 vs. 8.9 ± 2.2 mmHg; p = 0.020) without affecting splanchnic
blood-flow or systemic hemodynamics. The addition of propranolol to cilofexor additionally reduced
splanchnic inflow (−28%) but also mean arterial pressure (−25%) and heart rate (−37%). Conclusion:
The non-steroidal FXR agonist cilofexor decreased portal hypertension and reduced liver fibrosis
in NASH rats. While cilofexor seems to primarily decrease sinusoidal resistance in cirrhotic portal
hypertension, the combination with propranolol additionally reduced mesenteric hyperperfusion
Permissiveness of bovine epithelial cells from lung, intestine, placenta and udder for infection with Coxiella burnetii
Hamburger Südsee-Expedition (1908-1910)
2. 9 linear feet (7 boxes). Organization follows that of the original German text. Parts 1-3 called volumes 1-3 in the translations.Typescript of translation with photocopies of the German text. Never published. Gifts of Dr. Robert Kiste and Ms. Elizabeth A. Murphy have been combined to create files of the translations and materials used for the translations. A final English language transcription was compiled from these files, bound in three volumes and added to the Pacific Collection holdings under call number DU568.P7 H35 1983; it is recommended that researchers access the bound volumes first, as they are considered to be the completed translations. This manuscript collection in essence documents the translation process, and includes previous draft translations
Distinct conformational and energetic features define the specific recognition of (di)aromatic peptide motifs by PEX14.
The cycling import receptor PEX5 and its membrane-located binding partner PEX14 are key constituents of the peroxisomal import machinery. Upon recognition of newly synthesized cargo proteins carrying a peroxisomal targeting signal type 1 (PTS1) in the cytosol, the PEX5/cargo complex docks at the peroxisomal membrane by binding to PEX14. The PEX14 N-terminal domain (NTD) recognizes (di)aromatic peptides, mostly corresponding to Wxxx(F/Y)-motifs, with nano-to micromolar affinity. Human PEX5 possesses eight of these conserved motifs distributed within its 320-residue disordered N-terminal region. Here, we combine biophysical (ITC, NMR, CD), biochemical and computational methods to characterize the recognition of these (di)aromatic peptides motifs and identify key features that are recognized by PEX14. Notably, the eight motifs present in human PEX5 exhibit distinct affinities and energetic contributions for the interaction with the PEX14 NTD. Computational docking and analysis of the interactions of the (di)aromatic motifs identify the specific amino acids features that stabilize a helical conformation of the peptide ligands and mediate interactions with PEX14 NTD. We propose a refined consensus motif ExWΦxE(F/Y)Φ for high affinity binding to the PEX14 NTD and discuss conservation of the (di)aromatic peptide recognition by PEX14 in other species
A novel Pex14 protein-interacting site of human Pex5 is critical for matrix protein import into peroxisomes.
Protein import into peroxisomes relies on the import receptor Pex5, which recognizes proteins with a peroxisomal targeting signal 1 (PTS1) in the cytosol and directs them to a docking complex at the peroxisomal membrane. Receptor-cargo docking occurs at the membrane-associated protein Pex14. In human cells, this interaction is mediated by seven conserved diaromatic penta-peptide motifs (WXXX(F/Y) motifs) in the N-terminal half of Pex5 and the N-terminal domain of Pex14. A systematic screening of a Pex5 peptide library by ligand blot analysis revealed a novel Pex5-Pex14 interaction site of Pex5. The novel motif composes the sequence LVAEF with the evolutionarily conserved consensus sequence LVXEF. Replacement of the amino acid LVAEF sequence by alanines strongly affects matrix protein import into peroxisomes in vivo. The NMR structure of a complex of Pex5-(57-71) with the Pex14-N-terminal domain showed that the novel motif binds in a similar α-helical orientation as the WXXX(F/Y) motif but that the tryptophan pocket is now occupied by a leucine residue. Surface plasmon resonance analyses revealed 33 times faster dissociation rates for the LVXEF ligand when compared with a WXXX(F/Y) motif. Surprisingly, substitution of the novel motif with the higher affinity WXXX(F/Y) motif impairs protein import into peroxisomes. These data indicate that the distinct kinetic properties of the novel Pex14-binding site in Pex5 are important for processing of the peroxisomal targeting signal 1 receptor at the peroxisomal membrane. The novel Pex14-binding site may represent the initial tethering site of Pex5 from which the cargo-loaded receptor is further processed in a sequential manner